L

LYCA

LYCA

UnknownUnknown

Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.

Insider Sentiment
Based on recent trading activity
100%Bullish
Buy/Sell Ratio100% buys
BearishBullish
LYCA Live QuoteReal-time
$33.07
+$3.07(+10.23%)1M
Day Range$31.00 – $34.59
Open$31.86
Previous Close$31.77
Volume422.1K
Key Financials & Valuation
Fundamental balance sheet & market metrics
HEALTHCARE
Market Cap$1.63B
P/E Ratio (TTM)24.5
Forward P/ENaN
EPS (TTM)$-1.04
Price to BookNaN
Dividend Yield0.65%
Beta (Volatility)1.18
IndustryBIOTECHNOLOGY
52-Week RangeCurrent: $33.07 (76%)
Low: $22.19High: $36.49
Wall Street Consensus
Sell
Analyst Rating
2.2/ 5.0
Target Price
$54.00-64.0% upside

Insider Buys

1

$37.65M

Insider Sales

0

$0

Total Volume

$37.65M

1 transactions

Net Activity

+$37.65M

Net buying

Proprietary Ratings
Calculated from Form 4 transactions
80CONFIDENCE

Sentiment Rating

Strong Accumulation

CEO Conviction Index

No Recent Signal

Key Drivers

  • •Strong buying bias: purchases represent 100% of total transaction value.
  • •Ultra-high accumulation: total purchase value exceeds $10M.
Score Methodology

The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:

  • +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
  • +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
  • +15CEO Buying: CEO committing own capital shows high conviction.
  • +10CFO Buying: CFO purchasing shares shows financial alignment.
Top Insiders
Most active traders
V
1

Venrock Healthcare Capital Partners Iii, L.P.

10%

1 buys0 sells

$37.65M total

Trading History
LYCA insider transactions from SEC Form 4 filings
DateInsiderTypeSharesPriceValueFiling

Oct 23, 2026

4 weeks ago

Venrock Healthcare Capital Partners Iii, L.P.

10%

10% Owner
Buy2.05M$18.41$37.65M
Sector & Industry Benchmarks
Unknown Comparison Overview
Industry Buy Conviction6%
LYCA Buy Conviction100%
Industry Rank#0 of 569
Volume Contribution0.2%
Total Industry Activity$16.52B

LYCA has an insider buy conviction of 100%, compared to the Unknown sector buy average of 6%.

Insider Trading Summary & Commentary
Automated executive transaction analysis for LYCA

Over the last 90 days, corporate insiders at LYCA (LYCA) engaged in a total of 1 transactions reported via SEC Form 4 filings. Among these, 1 were open-market purchases and 0 were sales. The total volume of insider trading reached $37.65M.

The net insider activity for LYCA shows a net buying bias of $37.65M. This activity represents a 100% buy ratio, suggesting that insiders are currently strongly bullish on the company's near-term outlook relative to recent history.

The most notable individual transaction was a Purchase by Venrock Healthcare Capital Partners Iii, L.P. (10%), who traded 2.05M shares valued at $37.65M on Oct 23, 2026.

Live Market News & Developments
Aggregated real-time headlines for LYCA (LYCA)
6 updates

Lycia Therapeutics, Inc. (LYCA) Stock Price, News, Quote & History

Yahoo! Finance Canada26d ago

symbol__ Stock Quote Price and Forecast

CNN27d ago

New Analyst Forecast: $LYCA Given $48 Price Target

Quiver QuantitativeYesterday

LYCA - Lycia Therapeutics Inc Stock Price and Quote

Finviz28d ago

Lycia Therapeutics, Inc. (LYCA) Stock Price, Quote, News & Analysis

Seeking Alpha42d ago

A biotech CEO will speak in London Nov. 18; viewers may watch live online.

Stock Titan9d ago

FAQs About LYCA Insider Trading

Answers to common questions regarding corporate filings and executive sentiment for LYCA.

Based on SEC Form 4 disclosures, the Insider Confidence Score for LYCA is currently 80/100, which reflects a strong accumulation bias. This calculation accounts for a total of 1 purchases and 0 sales by company executives over the last 90 days.

The CEO Conviction Index for LYCA is rated as "No Recent Signal". Executive buying is typically a strong vote of confidence as C-level leaders have the most intimate knowledge of their firm's prospects. Officer selling, on the other hand, is often routine and does not automatically signal operational weakness.

No. Insider tracking is a highly informative technical signal that indicates executive sentiment, but it should not be the sole basis for a transaction. Investors should combine this filing analysis with company financials, sector trends, and risk management criteria.